ERBB2 and neoplasm: Several studies aim to clarify the tumor regression mechanism of HER2-positive tumors undergoing neoadjuvant therapy, given their specific immunological aspect [6]. A mechanism can inactivate tumor cell growth or death with the opposite action throughout the oncogenic promotion [7-9].